-
1
-
-
84874642212
-
Epidemiology of breast cancer, current figures and trends
-
PID: 24771909
-
Eisemann N, Waldmann A, Katalinic A (2013) Epidemiology of breast cancer, current figures and trends. Geburtsh Frauenheilk 73:130–135
-
(2013)
Geburtsh Frauenheilk
, vol.73
, pp. 130-135
-
-
Eisemann, N.1
Waldmann, A.2
Katalinic, A.3
-
3
-
-
0022455625
-
The relation between survival and age at diagnosis in breast cancer
-
COI: 1:STN:280:DyaL283osV2isg%3D%3D, PID: 3736639
-
Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563
-
(1986)
N Engl J Med
, vol.315
, pp. 559-563
-
-
Adami, H.O.1
Malker, B.2
Holmberg, L.3
Persson, I.4
Stone, B.5
-
4
-
-
49149119336
-
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
-
PID: 18612148
-
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330
-
(2008)
J Clin Oncol
, vol.26
, pp. 3324-3330
-
-
Anders, C.K.1
Hsu, D.S.2
Broadwater, G.3
Acharya, C.R.4
Foekens, J.A.5
Zhang, Y.6
-
5
-
-
70450184089
-
Breast cancer in young women: poor survival despite intensive treatment
-
PID: 19907646
-
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4:e7695
-
(2009)
PLoS One
, vol.4
, pp. e7695
-
-
Fredholm, H.1
Eaker, S.2
Frisell, J.3
Holmberg, L.4
Fredriksson, I.5
Lindman, H.6
-
6
-
-
0036299594
-
Very young women (<35 years) with operable breast cancer: features of disease at presentation
-
COI: 1:STN:280:DC%2BD387ltl2gtw%3D%3D, PID: 11886005
-
Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G et al (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279
-
(2002)
Ann Oncol
, vol.13
, pp. 273-279
-
-
Colleoni, M.1
Rotmensz, N.2
Robertson, C.3
Orlando, L.4
Viale, G.5
Renne, G.6
-
7
-
-
0043237300
-
Do young breast cancer patients have worse outcomes?
-
PID: 12943818
-
Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY (2003) Do young breast cancer patients have worse outcomes? J Surg Res 113:109–113
-
(2003)
J Surg Res
, vol.113
, pp. 109-113
-
-
Maggard, M.A.1
O’Connell, J.B.2
Lane, K.E.3
Liu, J.H.4
Etzioni, D.A.5
Ko, C.Y.6
-
8
-
-
0036114199
-
Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer
-
PID: 12020397
-
Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B et al (2002) Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 3:65–72
-
(2002)
Clin Breast Cancer
, vol.3
, pp. 65-72
-
-
Dubsky, P.C.1
Gnant, M.F.2
Taucher, S.3
Roka, S.4
Kandioler, D.5
Pichler-Gebhard, B.6
-
9
-
-
77957710541
-
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
-
COI: 1:CAS:528:DC%2BC3cXht1elsLjK, PID: 20697801
-
Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133–140
-
(2010)
Breast Cancer Res Treat
, vol.124
, pp. 133-140
-
-
Huober, J.1
von Minckwitz, G.2
Denkert, C.3
Tesch, H.4
Weiss, E.5
Zahm, D.M.6
-
10
-
-
84862303759
-
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
-
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804
-
(2012)
J Clin Oncol
, vol.30
, pp. 1796-1804
-
-
von Minckwitz, G.1
Untch, M.2
Blohmer, J.U.3
Costa, S.D.4
Eidtmann, H.5
Fasching, P.A.6
-
11
-
-
84904188903
-
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
-
PID: 24529560
-
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172
-
(2014)
Lancet
, vol.384
, pp. 164-172
-
-
Cortazar, P.1
Zhang, L.2
Untch, M.3
Mehta, K.4
Costantino, J.P.5
Wolmark, N.6
-
12
-
-
84869503259
-
The european society of breast cancer specialists recommendations for the management of young women with breast cancer
-
PID: 23116682
-
Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L et al (2012) The european society of breast cancer specialists recommendations for the management of young women with breast cancer. Eur J Cancer 48:3355–3377
-
(2012)
Eur J Cancer
, vol.48
, pp. 3355-3377
-
-
Cardoso, F.1
Loibl, S.2
Pagani, O.3
Graziottin, A.4
Panizza, P.5
Martincich, L.6
-
13
-
-
84863978873
-
Breast cancer in young women–a clinical challenge to be addressed in a multidisciplinary setting
-
Cardoso F, Harbeck N (2012) Breast cancer in young women–a clinical challenge to be addressed in a multidisciplinary setting. Breast Care 7:193–194
-
(2012)
Breast Care
, vol.7
, pp. 193-194
-
-
Cardoso, F.1
Harbeck, N.2
-
14
-
-
21044454272
-
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group
-
von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676–2685
-
(2005)
J Clin Oncol
, vol.23
, pp. 2676-2685
-
-
von Minckwitz, G.1
Raab, G.2
Caputo, A.3
Schütte, M.4
Hilfrich, J.5
Blohmer, J.U.6
-
15
-
-
19944426993
-
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
-
von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63
-
(2005)
Ann Oncol
, vol.16
, pp. 56-63
-
-
von Minckwitz, G.1
Blohmer, J.U.2
Raab, G.3
Löhr, A.4
Gerber, B.5
Heinrich, G.6
-
16
-
-
43149114454
-
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
-
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100:552–562
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 552-562
-
-
von Minckwitz, G.1
Kümmel, S.2
Vogel, P.3
Hanusch, C.4
Eidtmann, H.5
Hilfrich, J.6
-
17
-
-
43149120682
-
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
-
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542–551
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 542-551
-
-
von Minckwitz, G.1
Kümmel, S.2
Vogel, P.3
Hanusch, C.4
Eidtmann, H.5
Hilfrich, J.6
-
18
-
-
77951624086
-
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from GeparQuattro study
-
COI: 1:CAS:528:DC%2BC3cXmtlSksrg%3D, PID: 20308670
-
Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from GeparQuattro study. J Clin Oncol 28:2024–2031
-
(2010)
J Clin Oncol
, vol.28
, pp. 2024-2031
-
-
Untch, M.1
Rezai, M.2
Loibl, S.3
Fasching, P.A.4
Huober, J.5
Tesch, H.6
-
19
-
-
67649921349
-
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer
-
PID: 19364964
-
Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I et al (2009) Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938–2945
-
(2009)
J Clin Oncol
, vol.27
, pp. 2938-2945
-
-
Untch, M.1
Möbus, V.2
Kuhn, W.3
Muck, B.R.4
Thomssen, C.5
Bauerfeind, I.6
-
20
-
-
80052414508
-
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer–results at the time of surgery
-
COI: 1:STN:280:DC%2BC3MfptFClug%3D%3D, PID: 21385882
-
Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W et al (2011) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer–results at the time of surgery. Ann Oncol 22:1988–1998
-
(2011)
Ann Oncol
, vol.22
, pp. 1988-1998
-
-
Untch, M.1
Fasching, P.A.2
Konecny, G.E.3
von Koch, F.4
Conrad, U.5
Fett, W.6
-
21
-
-
80052401850
-
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis
-
COI: 1:STN:280:DC%2BC3MfptFCltQ%3D%3D, PID: 21382868
-
Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C et al (2011) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis. Ann Oncol 22:1999–2006
-
(2011)
Ann Oncol
, vol.22
, pp. 1999-2006
-
-
Untch, M.1
von Minckwitz, G.2
Konecny, G.E.3
Conrad, U.4
Fett, W.5
Kurzeder, C.6
-
22
-
-
79957601951
-
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups
-
COI: 1:CAS:528:DC%2BC3MXhtlWisLbM, PID: 21788566
-
Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357
-
(2011)
J Clin Oncol
, vol.29
, pp. 3351-3357
-
-
Untch, M.1
Fasching, P.A.2
Konecny, G.E.3
Hasmüller, S.4
Lebeau, A.5
Kreienberg, R.6
-
23
-
-
78651081149
-
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
-
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156
-
(2011)
Breast Cancer Res Treat
, vol.125
, pp. 145-156
-
-
von Minckwitz, G.1
Untch, M.2
Nüesch, E.3
Loibl, S.4
Kaufmann, M.5
Kümmel, S.6
-
24
-
-
84856291930
-
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
-
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309
-
(2012)
N Engl J Med
, vol.366
, pp. 299-309
-
-
von Minckwitz, G.1
Eidtmann, H.2
Rezai, M.3
Fasching, P.A.4
Tesch, H.5
Eggemann, H.6
-
25
-
-
84856444501
-
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
-
COI: 1:CAS:528:DC%2BC38XitVSmurc%3D, PID: 22257523
-
Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135–144
-
(2012)
Lancet Oncol
, vol.13
, pp. 135-144
-
-
Untch, M.1
Loibl, S.2
Bischoff, J.3
Eidtmann, H.4
Kaufmann, M.5
Blohmer, J.U.6
-
26
-
-
0035425528
-
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
-
von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al (2001) Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 19:3506–3515
-
(2001)
J Clin Oncol
, vol.19
, pp. 3506-3515
-
-
von Minckwitz, G.1
Costa, S.D.2
Raab, G.3
Blohmer, J.U.4
Eidtmann, H.5
Hilfrich, J.6
-
27
-
-
84946504656
-
-
Accessed 02 Feb 2015
-
http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/march2012/14_2012E_Breast_Cancer_Specific_Situations.pdf Accessed 02 Feb 2015
-
-
-
-
28
-
-
84946504657
-
-
Accessed 02 Feb 2015
-
http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/march2012/13_2012E_Adjuvant_Radiotherapy.pdf Accessed 02 Feb 2015
-
-
-
-
29
-
-
20044377408
-
Patterns of treatment effects in subsets of patients in clinical trials
-
PID: 15208206
-
Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481
-
(2004)
Biostatistics
, vol.5
, pp. 465-481
-
-
Bonetti, M.1
Gelber, R.D.2
-
30
-
-
80054005684
-
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy
-
PID: 21900114
-
Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL et al (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885–3891
-
(2011)
J Clin Oncol
, vol.29
, pp. 3885-3891
-
-
Arvold, N.D.1
Taghian, A.G.2
Niemierko, A.3
Abi Raad, R.F.4
Sreedhara, M.5
Nguyen, P.L.6
-
31
-
-
84857700943
-
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
-
COI: 1:CAS:528:DC%2BC38Xjt1Wltb4%3D, PID: 22261811
-
Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M et al (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18:1341–1351
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1341-1351
-
-
Azim, H.A.1
Michiels, S.2
Bedard, P.L.3
Singhal, S.K.4
Criscitiello, C.5
Ignatiadis, M.6
-
32
-
-
84856636292
-
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
-
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444
-
(2012)
Lancet
, vol.379
, pp. 432-444
-
-
Peto, R.1
Davies, C.2
Godwin, J.3
Gray, R.4
Pan, H.C.5
Clarke, M.6
-
33
-
-
84886615995
-
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial
-
COI: 1:CAS:528:DC%2BC3sXhtlCqs7bP, PID: 23752109
-
Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31:2692–2698
-
(2013)
J Clin Oncol
, vol.31
, pp. 2692-2698
-
-
Partridge, A.H.1
Gelber, S.2
Piccart-Gebhart, M.J.3
Focant, F.4
Scullion, M.5
Holmes, E.6
-
34
-
-
34347223994
-
Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society
-
PID: 17515570
-
Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368
-
(2007)
J Clin Oncol
, vol.25
, pp. 2360-2368
-
-
Ahn, S.H.1
Son, B.H.2
Kim, S.W.3
Kim, S.I.4
Jeong, J.5
Ko, S.S.6
-
35
-
-
85181122894
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
-
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Godwin J, Gray R, Clarke M, Cutter D, Darby S et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
-
(2011)
Lancet
, vol.378
, pp. 771-784
-
-
Godwin, J.1
Gray, R.2
Clarke, M.3
Cutter, D.4
Darby, S.5
-
36
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
COI: 1:CAS:528:DC%2BD1MXhvVyisbk%3D, PID: 19213681
-
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691
-
(2009)
N Engl J Med
, vol.360
, pp. 679-691
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
Luschin-Ebengreuth, G.4
Pöstlberger, S.5
Menzel, C.6
-
37
-
-
84921838679
-
Adjuvant ovarian suppression in premenopausal breast cancer
-
COI: 1:CAS:528:DC%2BC2MXisFGrtb4%3D, PID: 25495490
-
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446
-
(2015)
N Engl J Med
, vol.372
, pp. 436-446
-
-
Francis, P.A.1
Regan, M.M.2
Fleming, G.F.3
Láng, I.4
Ciruelos, E.5
Bellet, M.6
-
38
-
-
0345963033
-
Factors influencing the effect of age on prognosis in breast cancer: population based study
-
COI: 1:STN:280:DC%2BD3c7ktlKitw%3D%3D, PID: 10678859
-
Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474–478
-
(2000)
BMJ
, vol.320
, pp. 474-478
-
-
Kroman, N.1
Jensen, M.B.2
Wohlfahrt, J.3
Mouridsen, H.T.4
Andersen, P.K.5
Melbye, M.6
-
39
-
-
84946491431
-
Independent prognostic value of age depends on breast cancer subtype
-
Brouckaert O, Salihi R, Laenen A, Vanderhaegen J, Amant F, Leunen K et al (2012) Independent prognostic value of age depends on breast cancer subtype. Cancer Res 72(24):7–29
-
(2012)
Cancer Res
, vol.72
, Issue.24
, pp. 7-29
-
-
Brouckaert, O.1
Salihi, R.2
Laenen, A.3
Vanderhaegen, J.4
Amant, F.5
Leunen, K.6
-
40
-
-
84879417845
-
The prognostic impact of age in patients with triple-negative breast cancer
-
PID: 23460246
-
Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN et al (2013) The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat 138:591–599
-
(2013)
Breast Cancer Res Treat
, vol.138
, pp. 591-599
-
-
Liedtke, C.1
Hess, K.R.2
Karn, T.3
Rody, A.4
Kiesel, L.5
Hortobagyi, G.N.6
|